[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ECSP088411A - Uso de sdf-1 para el tratamiento y/o prevención de enfermedades neurológicas. - Google Patents

Uso de sdf-1 para el tratamiento y/o prevención de enfermedades neurológicas.

Info

Publication number
ECSP088411A
ECSP088411A EC2008008411A ECSP088411A ECSP088411A EC SP088411 A ECSP088411 A EC SP088411A EC 2008008411 A EC2008008411 A EC 2008008411A EC SP088411 A ECSP088411 A EC SP088411A EC SP088411 A ECSP088411 A EC SP088411A
Authority
EC
Ecuador
Prior art keywords
sdf
prevention
treatment
neurological diseases
neurological
Prior art date
Application number
EC2008008411A
Other languages
English (en)
Inventor
Ursula Boschert
Amanda Proudfoot
Linda Kadi
Pierre Alain Vitte
Jerome Wojcik
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Publication of ECSP088411A publication Critical patent/ECSP088411A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere al uso de SDF-1, o de un agonista de actividad de SDF-1, para el tratamiento y/o prevención de una enfermedad neurológica.
EC2008008411A 2005-10-31 2008-04-29 Uso de sdf-1 para el tratamiento y/o prevención de enfermedades neurológicas. ECSP088411A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05110206 2005-10-31
US73414205P 2005-11-07 2005-11-07

Publications (1)

Publication Number Publication Date
ECSP088411A true ECSP088411A (es) 2008-05-30

Family

ID=38006228

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008411A ECSP088411A (es) 2005-10-31 2008-04-29 Uso de sdf-1 para el tratamiento y/o prevención de enfermedades neurológicas.

Country Status (2)

Country Link
EC (1) ECSP088411A (es)
IL (1) IL190842A0 (es)

Also Published As

Publication number Publication date
IL190842A0 (en) 2008-11-03

Similar Documents

Publication Publication Date Title
AR058173A1 (es) Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
CR10730A (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
PA8637301A1 (es) Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa
AR059390A1 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
CL2007002017A1 (es) Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple.
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
EA200702529A1 (ru) Фунгицидная комбинация биологически активных веществ
AR057643A1 (es) Lacosamida para terapia adjunta
WO2007013666A3 (en) Anti-tumor agents comprising r-spondins
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
GT200600077A (es) Imidazoles sustituidos con heterociclilamida
UY28313A1 (es) Nonadepsipeptidos acilados
DOP2006000024A (es) Tiazolidinonas, su preparación y su uso como medicamento
ITRM20050446A1 (it) Uso di stilbeni idrossilati e glucosidati per la prevenzione ed il trattamento di patologie oculari.
EA200501528A1 (ru) Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
HN2005030779A (es) Nonadepsipeptidos acilados ii
HN2003000104A (es) Derivados de ciclopenteno
AR064214A1 (es) Uso de epotilonas en el tratamiento de la osteoporosis y enfermedades relacionadas
ECSP088411A (es) Uso de sdf-1 para el tratamiento y/o prevención de enfermedades neurológicas.
DK1713438T3 (da) Medicinsk sæbe
NO20072048L (no) Anvendelse av IL-17F for behandling og/eller forebygging av neurologiske sykdommer.